Bandingkan Harga & Kinerja Intikeramik Alamasri Industri Tbk. (IKAI) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Intikeramik Alamasri Industri Tbk. dan Organon Pharma Indonesia Tbk.: Intikeramik Alamasri Industri Tbk. diperdagangkan di Rp20 (kapitalisasi pasar 279,42 M, volume 24 jam 10,68 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Intikeramik Alamasri Industri Tbk. jauh lebih besar — sekitar 2,7× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| IKAI | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 279,42 M | 104,4 M |
Volume | 10,68 jt | — |
Lot | 106,77 rb | — |
Perputaran | 214,53 jt | — |
Harga Rata-rata | 20,09 | — |
Nilai Transaksi | 214,53 jt | — |
Harga Ekuilibrium Indikatif | 20 | — |
Volume Ekuilibrium Indikatif | 10,92 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Intikeramik Alamasri Industri Tbk.
PT Intikeramik Alamasri Industri Tbk (the Company) was established under the name PT Intikeramik Alamasri Indah based on notarial deed No. 38 dated June 26, 1991 and was amended with notarial deed No. 16 dated December 14, 1991, both made by Raden Muhammad Hendarmawan, S.H., Notary in Jakarta. PT Intikeramik Alamasri Industri Tbk is the pioneer of large-scale porcelain tile manufacture in Indonesia and one of the largest producers in the Asia Pacific region. Porcelain tiles are superior in term of strength, durability and design versatility to natural stone as well as other synthetics such as glazed tiles. Porcelain is attractive and affordable for use in both commercial and residential developments and has strong following among international architects and interior designers. Intikeramik is seeking to build a leading profile in markets across Europe, America and Asia drawing upon its reputation for consistency, advanced manufacturing technology, a low cost base and substantial available capacity. The company has consolidation production capacity 6,600,000 m2 /year.
Selengkapnya di halaman IKAI →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
